Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today announced the completion of a Series D funding raise of $12.2 million. The company also announced the addition of two new directors to its board, positioning the company for accelerated growth.
SI-BONE, Inc., an innovative medical device company that pioneered the use of the iFuse Implant System® (“iFuse”), a triangular shaped minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, today announced FDA clearance and full U.S. commercial launch of the iFuse-3D™ Implant (“iFuse-3D”), the first-ever 3D-printed titanium implant for use in the SI joint.
-Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, has announced that it has named global research and development expert Bruno Dacquay as its new vice president of engineering.
Strata Oncology, Inc., a precision oncology company, today announced the launch of its 2.0 test, StrataNGS, a custom-designed, 90-gene targeted assay focused on actionable genetic alterations in tumor tissue, including standard of care markers and clinical trial eligibility markers.
Click below to view the latest news and updates from Arboretum Ventures.
The University of Alabama at Birmingham Comprehensive Cancer Center announces its partnership with Strata Oncology to provide patients with advanced or rare cancers with tumor profiling or sequencing at no cost. This will include primarily those with metastatic disease or whose tumors cannot be removed surgically, and will also be available to all glioblastoma and pancreatic cancer patients.
Aira, a mission-driven company dedicated to developing smart products and services that enable blind and low vision individuals (BVI) to lead healthier and more independent lives, today announced that it has raised $12 million in a Series B funding round led by JAZZ Venture Partners and Arboretum Ventures.
Employers are increasingly likely to offer health benefits that go beyond traditional coverage for injuries and illness, to support lifelong well-being.
NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermotherapy to treat endourological conditions, today announced the company’s Rezūm System has been used to safely and effectively treat more than 10,000 men suffering from benign prostatic hyperplasia (BPH) across the U.S. and Europe.
NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermotherapy technology to treat endourological conditions, was named a recipient of the 2017 Eureka! Innovation Awards, honoring the most innovative companies, products and ideas in Minnesota.
No more posts to load.
Load More Posts